U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07806773) titled 'Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer' on Sept. 01.
Brief Summary: The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer (NSCLC).
The primary objectives of this study are to determine the safety and tolerability and effectiveness of TUB-040, and/or recommended Phase 2 dose (RP2D).
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
NSCLC
Non Small Cell Lung Cancer
Intervention:
DRU...